CD274 and non-small cell lung carcinoma: About one‐third of the NSCLC patients without targetable alteration show high programmed cell death‐ligand 1 (PD‐L1) expression ≥50% and therefore qualify for pembrolizumab monotherapy6; the remaining majority is thus frequently treated with chemotherapy‐based therapy regimens.